secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2022-09-06T23:59:59+00:00
Accession:  0001193125-22-238883
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium to acquire Metacrine in all-stock deal; adds $33M cash, MET642 candidate
--------------------------------------------------------------------------------

- All-stock merger adds ~$33M cash to Equillium's balance sheet, extending runway into 2024.
- Transaction valued at 25% premium over Metacrine net cash (~$26M); EQ shares priced between $2.70 and $4.50.
- Equillium assumes $15M Metacrine debt from K2 HealthVentures; retires its own $10M Oxford/SVB facility.
- Acquisition includes MET642, a Phase 2-ready oral FXR agonist for ulcerative colitis; strategic partner sought.
- Preston Klassen (Metacrine CEO) appointed to Equillium board; no Metacrine employees retained. Closing late 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312522238883/0001193125-22-238883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312522238883/d336866d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-238883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer